TalkMarkets Newswire Blog | Talkmarkets | Page 1
Company News & Information

TalkMarkets Newswire is a premier service which disseminates and distributes critical news, press releases and information about a variety of companies. This information is seen by readers not only on TalkMarkets, but also goes out to our distribution partners which include such leading ... more


Latest Posts
1 to 16 of 25 Posts
1 2
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform.
Legacy Education Alliance Teams Up With The Cash Flow Academy
Legacy Education Alliance, Inc. announced that it has entered into a marketing and fulfillment agreement with The Cash Flow Academy.
DarioHealth Announces Two New Contracts Within The Employer Market
Dario's new employer clients include a contract for its full suite of digital therapeutic solutions.
SinglePoint Inc. Announces Updated Q4 2021 Revenue Milestones And Annual Revenue Projections For Solar-Centric Businesses For FY2022
SinglePoint Inc., today provided an update on forward-looking revenue guidance goals for the Company's solar-centric subsidiaries for Q4 2021
CNS Pharmaceuticals Commences Patient Enrollment In Potentially Pivotal Study Of Berubicin
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.
American Resources Corporation Selected As A Consortium Member In U.S. Department Of Energy Contract To Assess Northern Appalachian Critical And Rare Earth Elements
American Resources Corporation is a next-generation, environmentally, and socially responsible supplier of high-quality raw materials to the new infrastructure market.
Ituran Location And Control Ltd. Schedules First Quarter 2021 Results Release And Conference Call For Tuesday, May 25, 2021
The Company will also be hosting a conference that day at 9am Eastern Time. On the call, management will review and discuss the results, and will be available to answer investor questions.
Cidara Therapeutics Announces Agreement With Janssen To Develop And Commercialize AVCs For The Prevention And Treatment Of Influenza
Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak® antiviral platform that couple potent antivirals to a human antibody fragment.
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
SinglePoint Enters Into Letter Of Intent To Acquire EnergyWyze, LLC To Streamline, Optimize, And Maximize Solar Industry Lead Generation
Agreement signifies a key step towards solidifying a leadership position in the solar industry.
American Resources, Wholly Owned Subsidiary, American Rare Earth LLC Enters Into Joint Venture To Develop And Commercialize Critical Element And Graphene Technologies
Joint venture partners with Gerardine Botte, Ph.D., Texas Tech University Professor and Department Chair to develop and commercialize technologies production from carbon-based deposits.
American Resources Corporation Unveils Rare Earth Element Wholly Owned Subsidiary, American Rare Earth LLC
American Resources Corporation, a supplier of raw materials to the rapidly growing global infrastructure marketplace, today unveiled its wholly owned subsidiary, American Rare Earth LLC ("American Rare Earth").
Sonnet BioTherapeutics Receives $10.5 Million From Exercise Of Series A Warrants
Sonnet Bio announced today that, as part of the previously announced warrant exchange agreement, all 3,300,066 Series A Warrants have been exercised at a price of $3.19 per share. Gross proceeds to the Company were $10.5 Million.
Protalix BioTherapeutics Announces FDA Acceptance Of BLA For The Treatment Of Fabry Disease And Grants Priority Review
Priority Review is granted to therapies that the FDA determines have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder
VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.
CytoDyn Files Application With Nasdaq For Uplist
CytoDyn Inc., announced today it recently filed a comprehensive listing application package with The Nasdaq Stock Market to request an uplisting of the Company’s common stock.
1 to 16 of 25 Posts
1 2